Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines

MLA

Philippe Picaut, et al. “Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines.” Aesthetic Surgery Journal, vol. 40, Mar. 2019, pp. 93–104. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........ed5ebce083b4959893c4308fd18634c1&authtype=sso&custid=ns315887.

APA

Philippe Picaut, Said Hilton, Philippe Le Berre, Philippe Kestemont, Martina Kerscher, Marc Heckmann, Dominique Boineau, Benjamin Ascher, Ernst Magnus Noah, Berthold Rzany, Isaac Bodokh, & Magali Volteau. (2019). Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines. Aesthetic Surgery Journal, 40, 93–104.

Chicago

Philippe Picaut, Said Hilton, Philippe Le Berre, Philippe Kestemont, Martina Kerscher, Marc Heckmann, Dominique Boineau, et al. 2019. “Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines.” Aesthetic Surgery Journal 40 (March): 93–104. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........ed5ebce083b4959893c4308fd18634c1&authtype=sso&custid=ns315887.